Document is current
Any future updates will be listed below
-
Authors
Nishimura, Toshinobu https://orcid.org/0000-0002-5425-1708
Xu, Haojun https://orcid.org/0000-0001-9600-1945
Iwasaki, Masayuki https://orcid.org/0000-0002-3003-3853
Karigane, Daiki https://orcid.org/0000-0002-4017-5193
Saavedra, Brandon https://orcid.org/0000-0003-4211-9993
Takahashi, Yusuke https://orcid.org/0000-0001-6507-9088
Suchy, Fabian P. https://orcid.org/0000-0002-7187-5360
Monobe, Shinichiro
Martin, Renata M. https://orcid.org/0000-0003-2996-4260
Ohtaka, Manami
Nakanishi, Mahito
Burrows, Scott R. https://orcid.org/0000-0002-1430-0472
Cleary, Michael L. https://orcid.org/0000-0001-7127-3223
Majeti, Ravindra https://orcid.org/0000-0002-5814-0984
Shibuya, Akira
Nakauchi, Hiromitsu https://orcid.org/0000-0002-9841-6973
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science
Weston Havens Foundation
California Institute for Regenerative Medicine (LA1_C12-06917, QUEST DISC2-08874)
- License Information
-
More Information
Article History
Received: 24 September 2019
Revised: 27 June 2020
Accepted: 14 July 2020
First Online: 23 July 2020
Compliance with ethical standards
:
: RM is a co-founder, equity holder, and serves on the Board of Directors of Forty Seven, Inc. HN is a co-founder, member of the scientific advisory board, and shareholder of Megakaryon Corp., iCELL, Inc. and Century Therapeutics, LLC. The remaining authors declare no conflict of interest.
